We are live on ! Find out more
ELDN icon

Eledon Pharmaceuticals
ELDN

15 hedge funds and large institutions have $15M invested in Eledon Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

0.03% less ownership

Funds ownership: 2.34% → 2.31% (-0.03%)

7% less capital invested

Capital invested by funds: $16.1M → $15M (-$1.11M)

21% less funds holding

Funds holding: 19 → 15 (-4)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
15
Holders Change
-4
Holders Change %
-21.05%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LSC
Lyon Street Capital
California
+$585K
2
Renaissance Technologies
Renaissance Technologies
New York
+$97.3K
3
Millennium Management
Millennium Management
New York
+$46.8K
4
TRCT
Tower Research Capital (TRC)
New York
+$22.2K
5
UBS Group
UBS Group
Switzerland
+$14.1K

Top Sellers

Rank Fund Capital Flow
1
ECM
Element Capital Management
New York
-$145K
2
Goldman Sachs
Goldman Sachs
New York
-$76K
3
Deutsche Bank
Deutsche Bank
Germany
-$13.6K
4
Bank of America
Bank of America
North Carolina
-$3K
5
BlackRock
BlackRock
New York
-$2.49K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$13.2M – – –
LSC
2
Lyon Street Capital
California
$873K +$585K +7,045 +311%
Renaissance Technologies
3
Renaissance Technologies
New York
$437K +$97.3K +1,172 +34%
Vanguard Group
4
Vanguard Group
Pennsylvania
$235K +$10.5K +126 +5%
BlackRock
5
BlackRock
New York
$82K -$2.49K -30 -3%
D.E. Shaw & Co
6
D.E. Shaw & Co
New York
$82K – – –
Millennium Management
7
Millennium Management
New York
$53K +$46.8K +564 New
TRCT
8
Tower Research Capital (TRC)
New York
$29K +$22.2K +267 +607%
UBS Group
9
UBS Group
Switzerland
$18K +$14.1K +170 +773%
MAM
10
Meeder Asset Management
Ohio
$5K – – –
Royal Bank of Canada
11
Royal Bank of Canada
Ontario, Canada
$2K – – –
Deutsche Bank
12
Deutsche Bank
Germany
$1K -$13.6K -164 -90%
ECM
13
Element Capital Management
New York
– -$145K -1,376 Closed
Goldman Sachs
14
Goldman Sachs
New York
– -$76K -719 Closed
Bank of America
15
Bank of America
North Carolina
– -$3K -25 Closed
Creative Planning
16
Creative Planning
Kansas
– -$1K -8 Closed
Morgan Stanley
17
Morgan Stanley
New York
– -$332 -4 -67%
Barclays
18
Barclays
United Kingdom
– -$249 -3 Closed

ELDN Hedge Fund Activity: Q3 2017 in Review

15 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q3 2017, worth a combined $15M — down 6.9% from $16.1M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ELDN and 1 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 5 added.

The largest buyer was Lyon Street Capital, adding an estimated $585K. The largest seller was Element Capital Management, exiting entirely with an estimated $145K sold.

  • 15 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q3 2017, down from 19 in Q2 2017.
  • Funds reported $15M of Eledon Pharmaceuticals stock for Q3 2017, down 6.9% quarter-over-quarter.
  • 1 fund opened new Eledon Pharmaceuticals positions in Q3 2017 and 5 closed out, a net change of -4 holders.
  • The largest Eledon Pharmaceuticals buyer in Q3 2017 was Lyon Street Capital, an estimated $585K added.
  • The largest Eledon Pharmaceuticals seller in Q3 2017 was Element Capital Management, an estimated $145K sold.

Based on aggregated 13F filings for Q3 2017.